Inscrição YC de GEn1E Lifesciences
GEn1E Lifesciences passou pela Y Combinator no batch Summer 2019 como uma empresa Healthcare. Abaixo: o que a empresa faz, quem a fundou e sua inscrição para a YC, reconstruída pergunta por pergunta no formulário real da YC.
- Batch YC
- Summer 2019
- Indústria
- HealthcareTherapeutics
- Status
- Active
- Lançada
- 2022
Fundadores
Ritu LalFounder
O que GEn1E Lifesciences faz
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.
Inscrição YC de GEn1E Lifesciences, reconstruída
Inscrição Y Combinator
GEn1E Lifesciences, lote Summer 2019. As verdadeiras perguntas do formulário, respondidas com dados públicos.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
GEn1E Lifesciences
AI platform accelerating therapies for rare diseases
We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.
We live in Palo Alto, CA, and the company is based here.
Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.
21 respostas a mais na inscrição completa
Founders, Progress, Idea, Equity, Curious, Batch Preference estão na versão completa. Crie uma conta gratuita para abri-la no YC Insights, ao lado de todos os outros batches da YC.
Perguntas Frequentes
Esta é a inscrição real da YC de GEn1E Lifesciences?
Não. A Y Combinator mantém as inscrições submetidas em privado. Esta é uma reconstrução: as perguntas reais do formulário da YC, respondidas a partir dos dados públicos de GEn1E Lifesciences (notas de lançamento, históricos de fundadores, descrição do produto). Mostra como uma empresa como GEn1E Lifesciences se apresentaria à YC, não o texto que eles submeteram.
Em qual batch da YC GEn1E Lifesciences esteve?
GEn1E Lifesciences fez parte do batch Summer 2019 da Y Combinator.
Quem fundou o GEn1E Lifesciences?
O GEn1E Lifesciences foi fundado por Ritu Lal.
O que o GEn1E Lifesciences faz?
AI platform accelerating therapies for rare & inflammatory diseases.
Como eu leio o application completo reconstruído?
Crie uma conta gratuita no Round Funded. A versão completa de 26 respostas do application do GEn1E Lifesciences, e de todos os outros lotes do YC, está no YC Insights.
Mais startups YC como GEn1E Lifesciences
